Effect of selective and reversible MAO inhibitors on dopamine outflow in rat striatum: a microdialysis study.
The effect of reversible inhibitors of the monoamine oxidase type A (MAO-A), moclobemide (Aurorix) and Ro 41-1049 (20 mg/kg i.p. each), as well as of reversible inhibitors of the MAO type B (MAO-B), Ro 19-6327 (1 mg/kg i.p.), on the outflow of dopamine (DA), 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) was studied in the rat by transstriatal microdialysis. Reversible MAO-A inhibitors markedly increased the output of DA and concomitantly decreased the output of DOPAC and HVA. These effects were absent with the highly selective MAO-B inhibitor Ro 19-6327.
Colzi
A
A
Pharmaceutical Research Department, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
d'Agostini
F
F
Kettler
R
R
Borroni
E
E
Da Prada
M
M
D015102:3,4-Dihydroxyphenylacetic Acid / Q000378:metabolism; D000818:Animals; D001549:Benzamides; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism*; D003641:Deamination; D003956:Dialysis; D004298:Dopamine / Q000378:metabolism*; D006719:Homovanillic Acid / Q000378:metabolism; D008297:Male; D020912:Moclobemide; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology*; D010848:Picolinic Acids; D051381:Rats; D011919:Rats, Inbred Strains; D013844:Thiazoles
D001549:Benzamides; D008996:Monoamine Oxidase Inhibitors; D010848:Picolinic Acids; D013844:Thiazoles; D015102:3,4-Dihydroxyphenylacetic Acid; C063456:Ro 41-1049; C059303:lazabemide; D020912:Moclobemide; D004298:Dopamine; D006719:Homovanillic Acid